Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism

Talin Gulesserian; Gregor Hron; Georg Endler; Sabine Eichinger; Oswald Wagner; Paul A. Kyrle

doi:10.1160/TH05-09-0601

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(01): 65-67
DOI: 10.1160/TH05-09-0601

Rapid and Short Communication

Schattauer GmbH

Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism

Authors

Talin Gulesserian

¹Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine

²Clinical Institute of Medical and Chemical Laboratory Diagnostics
Gregor Hron

³Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
Georg Endler

²Clinical Institute of Medical and Chemical Laboratory Diagnostics
Sabine Eichinger

³Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
Oswald Wagner

²Clinical Institute of Medical and Chemical Laboratory Diagnostics
Paul A. Kyrle

³Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

Abstract

Summary

Whether a single nucleotide polymorphism (1601 G>A) in the factor VII-activating protease gene (FSAP Marburg I) is a risk factor for venous thromboembolism (VTE) is unclear. We investigated the relevance of the variant with respect to recurrent VTE. 854 patients with a first unprovoked VTE were followed for an average of 41 months after discontinuation of anticoagulation. Study endpoint was symptomatic recurrent VTE. VTE recurred in 7 of 41 patients (17%) with and in 106 of 813 patients (13%) without the variant. After3 years, the probability of recurrence was 20.0% (95% CI, 5.3% to 34.6%) among patients with and 12.2% (95% CI, 9.6% to 14.8%) among those without FSAP MarburgI (p = 0. 5). The relative recurrence risk among carriers of the variant was 1.3 (95% CI, 0.6 to 2.8; p = 0.5) before and 1.5 (95% CI, 0.7 to 3.3; p = 0. 3) after adjustment for potentially confounding factors. We conclude that FSAP Marburg I is, if at all, only a mild factor for recurrent VTE. Patients with FSAP Marburg I most probably will not benefit from extended anticoagulation.

Keywords

Venous thrombosis - risk factor - recurrence - Marburg I polymorphism

Full Text

References

References
1 Anderson FA, Wheeler HB, Goldberg RJ. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
2 Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365: 1163-74.
3 Roemisch J, Feussner A, Vermohlen S. et al. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1999; 10: 471-9.
4 Roemisch J, Vermohlen S, Feussner A. et al. The F VII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999; 29: 292-9.
5 Roemisch J, Feussner A, Nerlich C. et al. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinolysis 2002; 13: 433-41.
6 Willeit J, Kiechl S, Weimer T. et al. Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003; 107: 667-70.
7 Hoppe B, Tolou F, Radtke H. et al. MarburgI polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005; 105: 1549-51.
8 Hoppe B, Heymann GA, Radtke H. et al. Association of Marburg I polymorphism of factor VII-activating protease with venous thromboembolism is limited to idiopathic events. Blood 2005; 105: 4899.
9 van Minkelen R, de Visser MC, Vos HL. et al. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thromboembolism. Blood 2005; 105: 4898.
10 Kyrle PA, Minar E, Bialonczyk C. et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-63.
11 Brandt JT, Triplett DA, Alving B. et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
12 Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980
13 Kaplan EL, Meier P. Nonparametric estimation from incomplete Observations. J Am Stat Assoc 1958; 53: 457-81.